Research progress on molecular targeted therapy for metastatic esophageal cancer pa-tients
10.3969/j.issn.1000-8179.2016.04.333
- VernacularTitle:转移性食管癌分子靶向治疗的研究进展
- Author:
Jie YUE
;
Zhentao YU
- Publication Type:Journal Article
- Keywords:
metastatic esophageal cancer;
molecular targeted therapy;
EGFR;
HER-2
- From:
Chinese Journal of Clinical Oncology
2016;43(4):170-172
- CountryChina
- Language:Chinese
-
Abstract:
Esophageal cancer is a highly aggressive malignant tumor of the digestive tract. Despite the continuous development of sur-gical techniques and multidisciplinary treatments, the prognosis and overall survival of esophageal cancer patients is still poor. In re-cent years, the development of new molecular targeted therapy has become well advanced. Drugs that target tumor-related signal pathways and block the transmission of downstream signals can inhibit the growth and metastasis of tumor cells. Currently, esopha-geal cancer-targeted drugs are rarely approved officially. HER-2 inhibitor represents these types of drugs because of its positive expres-sion of metastatic adenocarcinoma. However, studies on the preparation of new drugs are not extensive. In this paper, the research progress of a new targeted therapy for metastatic esophageal cancer is reviewed.
